These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 20724119)

  • 41. Efficacy of current agents used in the treatment of Gram-positive infections and the consequences of resistance.
    Segreti J
    Clin Microbiol Infect; 2005 May; 11 Suppl 3():29-35. PubMed ID: 15811022
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of linezolid in the treatment of complicated skin and soft tissue infections.
    Peppard WJ; Weigelt JA
    Expert Rev Anti Infect Ther; 2006 Jun; 4(3):357-66. PubMed ID: 16771613
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia.
    Scheetz MH; Wunderink RG; Postelnick MJ; Noskin GA
    Pharmacotherapy; 2006 Apr; 26(4):539-50. PubMed ID: 16553514
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Methicillin-resistant Staphylococcus aureus as a cause of community-acquired pneumonia--a critical review.
    Johnston BL
    Semin Respir Infect; 1994 Sep; 9(3):199-206. PubMed ID: 7831542
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of linezolid against Panton-Valentine leukocidin (PVL)-positive meticillin-resistant Staphylococcus aureus (MRSA) in a mouse model of haematogenous pulmonary infection.
    Yanagihara K; Kihara R; Araki N; Morinaga Y; Seki M; Izumikawa K; Kakeya H; Yamamoto Y; Yamada Y; Kohno S; Tsukamoto K; Kamihira S
    Int J Antimicrob Agents; 2009 Nov; 34(5):477-81. PubMed ID: 19665359
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Early appropriate therapy of Gram-positive bloodstream infections: the conservative use of new drugs.
    Grossi PA
    Int J Antimicrob Agents; 2009; 34 Suppl 4():S31-4. PubMed ID: 19931814
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A holistic approach to MRSA eradication in critically ill patients with MRSA pneumonia.
    Wenisch C; Laferl H; Szell M; Smolle KH; Grisold A; Bertha G; Krause R
    Infection; 2006 Jun; 34(3):148-54. PubMed ID: 16804658
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia.
    Rubinstein E; Corey GR; Stryjewski ME; Kanafani ZA
    Expert Opin Pharmacother; 2011 Dec; 12(17):2737-50. PubMed ID: 22077833
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of ME1036 against meticillin-resistant Staphylococcus aureus and vancomycin-insensitive S. aureus in a model of haematogenous pulmonary infection.
    Yanagihara K; Ohnishi Y; Morinaga Y; Nakamura S; Kurihara S; Seki M; Izumikawa K; Kakeya H; Yamamoto Y; Yamada Y; Kohno S; Kamihira S
    Int J Antimicrob Agents; 2008 Nov; 32(5):401-4. PubMed ID: 18715761
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vancomycin, unbeatable for methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia? Really?
    Luna CM; Bruno D; Aruj P
    Crit Care Med; 2010 Sep; 38(9):1910-2. PubMed ID: 20724890
    [No Abstract]   [Full Text] [Related]  

  • 52. [Methicillin-resistant Staphylococcus aureus (MRSA) infection--significance of MRSA in respiratory tract infection].
    Shigeno Y; Yamashiro T; Kusano N
    Rinsho Byori; 1990 Sep; 38(9):1005-15. PubMed ID: 2232262
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A network meta-analysis of antibiotics for treatment of hospitalised patients with suspected or proven meticillin-resistant Staphylococcus aureus infection.
    Bally M; Dendukuri N; Sinclair A; Ahern SP; Poisson M; Brophy J
    Int J Antimicrob Agents; 2012 Dec; 40(6):479-95. PubMed ID: 23102749
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serious infections caused by methicillin-resistant Staphylococcus aureus.
    Boucher H; Miller LG; Razonable RR
    Clin Infect Dis; 2010 Sep; 51 Suppl 2():S183-97. PubMed ID: 20731576
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of linezolid compared to vancomycin in an experimental model of pneumonia induced by methicillin-resistant Staphylococcus aureus in ventilated pigs.
    Martinez-Olondris P; Rigol M; Soy D; Guerrero L; Agusti C; Quera MA; Li Bassi G; Esperatti M; Luque N; Liapikou M; Filella X; Marco F; de la Bellacasa JP; Torres A
    Crit Care Med; 2012 Jan; 40(1):162-8. PubMed ID: 21926613
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The antimicrobial armamentarium: evaluating current and future treatment options.
    Bosso JA
    Pharmacotherapy; 2005 Oct; 25(10 Pt 2):55S-62S. PubMed ID: 16178676
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antibiotics currently used in the treatment of infections caused by Staphylococcus aureus.
    Rayner C; Munckhof WJ
    Intern Med J; 2005 Dec; 35 Suppl 2():S3-16. PubMed ID: 16271060
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
    Saravolatz LD; Stein GE; Johnson LB
    Clin Infect Dis; 2011 May; 52(9):1156-63. PubMed ID: 21467022
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical experience with recently approved antibiotics.
    Paterson DL
    Curr Opin Pharmacol; 2006 Oct; 6(5):486-90. PubMed ID: 16904377
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New Gram-positive antibiotics: better than vancomycin?
    van Hal SJ; Paterson DL
    Curr Opin Infect Dis; 2011 Dec; 24(6):515-20. PubMed ID: 21844804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.